![[(2R,3R,4R,5R)-3,4-diacetyloxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl acetate;hydrochloride chemical structure [(2R,3R,4R,5R)-3,4-diacetyloxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl acetate;hydrochloride (CAS: 63639-21-4) - Chemical Structure and Molecular Formula](/static/img/prod_pic/FT-0770520.png)
![[(2R,3R,4R,5R)-3,4-diacetyloxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl acetate;hydrochloride chemical structure thumbnail [(2R,3R,4R,5R)-3,4-diacetyloxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl acetate;hydrochloride (CAS: 63639-21-4) - Chemical Structure Thumbnail](/static/img/prod_pic/FT-0770520.png)
[(2R,3R,4R,5R)-3,4-diacetyloxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl acetate;hydrochloride
Catalog No: FT-0770520
CAS No: 63639-21-4
- Chemical Name: [(2R,3R,4R,5R)-3,4-diacetyloxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl acetate;hydrochloride
- Molecular Formula: C15H20ClN3O8
- Molecular Weight: 405.79
- InChI Key: DMDAYVSFFBNVOE-VNQMUNOFSA-N
- InChI: InChI=1S/C15H19N3O8.ClH/c1-7(19)23-6-10-12(24-8(2)20)13(25-9(3)21)14(26-10)18-5-4-11(16)17-15(18)22;/h4-5,10,12-14H,6H2,1-3H3,(H2,16,17,22);1H/t10-,12-,13-,14-;/m1./s1
Assay | Pack Size | Price | Stock | Action |
---|---|---|---|---|
98% | 1g | N/A | N/A | |
98% | 5g | N/A | N/A | |
98% | Bulk Quantity | N/A | N/A |
Bolling_Point: | 530.3ºC at 760 mmHg |
---|---|
CAS: | 63639-21-4 |
MF: | C15H20ClN3O8 |
Density: | N/A |
Melting_Point: | 34-38ºC(lit.) |
Product_Name: | [(2R,3R,4R,5R)-3,4-diacetyloxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl acetate,hydrochloride |
Flash_Point: | >230 °F |
FW: | 405.78800 |
MF: | C15H20ClN3O8 |
---|---|
LogP: | 0.53260 |
Melting_Point: | 34-38ºC(lit.) |
Exact_Mass: | 405.09400 |
Bolling_Point: | 530.3ºC at 760 mmHg |
Flash_Point: | >230 °F |
FW: | 405.78800 |
Refractive_Index: | 1.4645-1.4665 |
PSA: | 149.04000 |
Personal_Protective_Equipment: | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
RIDADR: | NONH for all modes of transport |
Safety_Statements: | 23-24/25 |